Abstract In order to explore the effect of neoadjuvant chemotherapy (NACT) on clinical mid-course and pathological complete response (pCR) at surgery in different biological breast cancer subtypes. The GeparTrio study included 2,072 patients with operable or locally advanced breast cancer. After two cycles with docetaxel, doxorubicin and cyclophosphamide (TAC) patients were randomized according to their clinical response. Clinical and biological factors were assessed for predicting clinically mid-course response and pCR at surgery. The overall pCR rate, defined as no invasive residuals in breast and axilla, was 20.5%. The highest pCR rate of 57% was observed in patients below 40 years of age with triple negative or grade 3 tumors. Independent factors for mid-course response and pCR were: young age, non-T4 tumors, high grade, and hormone receptor status, the strongest single predictive factor. Within the biological subtypes, grading was an independent factor to predict pCR for luminal tumors, clinical tumor stage for the HER2 like tumors and age for the triple negative ones. Grading gave independent information for mid-course response within the triple negative group. No factor predicted mid-course response within the other groups. Grading and age can identify subgroups within the luminal and triple negative patients who have an increased benefit from NACT.
Introduction
Hormone receptor (HR) status is long known as independent predictor for chemotherapy response. Recently, we and others showed that the rate of pathological complete responses (pCR) differs between biological phenotypes [1] [2] [3] [4] [5] . In a smaller subset of the GeparDuo trial [6] , patients with a HR?/HER2-tumor had a very low chance of achieving a pCR but had still an excellent prognosis. Whereas patients with HR-/HER2? tumors have only an excellent prognosis when achieving a pCR [1] .
The identification of patients with a high likelihood of achieving a pCR using the biological phenotype along with age and grading is still of interest. Even in less chemosensitive tumors, a subgroup might still benefit from an anthracycline/taxane containing chemotherapy regimen, depending on age and grading.
A secondary endpoint of the GeparTrio study was to examine the correlations between different clinical and established biological markers and pCR to neoadjuvant chemotherapy (NACT) and to identify potential biological groups who will benefit from TAC chemotherapy. Since there is a relation between clinical (sonography or physical examination) mid-course response and pathological remission at surgery, the aim of the study was also to look for markers predicting mid-course response and whether these factors were different from those predicting a pathological complete response [7, 8] .
Methods
The GeparTrio trial was a multicenter, prospective, randomized, phase III trial with the primary goal of evaluating clinical activity of six to eight cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC) or two cycles of TAC followed by four cycles of vinorelbine and capecitabine (NX). One of the secondary endpoints of the study was to investigate clinical and biological markers that may predict early as well as late response to NACT.
From July 2002 until December 2005, 2,090 patients were registered for participation. Eligibility criteria were described elsewhere [7, 8] .
All patients started treatment with two cycles of TAC (docetaxel 75 mg/m 2 , doxorubicin 50 mg/m 2 , cyclophosphamide 500 mg/m 2 , on day 1, every 3 weeks). Clinical response was determined preferably by sonography or other clinical methods if sonography was considered as inappropriate by the investigator. Response was assessed by palpation (caliper) when the breast tumor could not be measured by sonography or in case of inflammatory disease by measurement of the skin lesion in case a palpable mass was missing. Patients with an early response were randomized to proceed with either four or six cycles of TAC, whereas patients without response were randomized either to continue with four cycles of TAC or to four cycles of NX (vinorelbine 25 mg/m 2 on days 1 and 8 plus capecitabine 1,000 mg/m 2 orally twice a day on days 1-14, every 3 weeks). None of the HER2? patients received trastuzumab during neoadjuvant treatment. Within 21 days after completion of chemotherapy and after overall assessment of response, patients had to undergo surgery and postoperative treatment according to standard recommendations. Patients with progression were excluded from randomization and treated at the discretion of the investigator. In patients with disease progression during further preoperative therapy immediate surgery was recommended.
Marker selection
The clinico-pathological markers available at baseline (see Supplementary Table S1a) were evaluated for response prediction.
Definition of response to neoadjuvant therapy
Response to NACT was evaluated twice. Mid-course response after TAC 92 was defined as a decrease of the product of the two largest perpendicular tumor diameters by at least 50%. Pathological response at surgery was based on the modified regression grading system by Sinn et al. [7] [8] [9] . For a better understanding, regression grade 3 (only non invasive residuals left in the breast) was divided into group 3a (without lymph node involvement) and 3b (with involved lymph nodes). Pathological complete response (pCR) was defined as a histopathological complete response of all invasive tumor cells from the breast and axillary tissue removed at surgery (ypT0, ypTis, ypN0 = regression grade 3a and 5) (Supplmentary Table S1b ).
The histological tumor type was defined according to the WHO definitions. The pathological examinations were performed by local pathologists of the participating sites; however, all pathology reports were centrally reviewed for pCR at the German Breast Group headquarters, Neu-Isenburg, Germany.
ER, PgR, and HER2 were measured locally at each participating center on tissue sections of the true/core-cutbiopsies obtained at the time of primary diagnosis before treatment. 
Statistics
Descriptive analyses were performed. Results were compared using the chi-square and Fisher 0 s exact test. A binary logistic regression for uni-and multivariate (full model) analysis was performed. All tests were two-sided with significance levels set at 0.05. With regard to the exploratory nature of this analysis, no adjustments were made for multiple comparisons. Statistical computations were performed in SPSS version 14.0.
Results
Of the 2,090 patients registered, 2,072 patients were randomized. For more detailed information on patients 0 availability please refer to the consort statement ( Fig. 1) . Except for the HER2 status, which was missing in 17% of the patients at primary diagnosis, all other factors were known in approximately 95% of the patients. Response after two cycles, TAC was observed in 1,400 of 2,034 patients (68.8%) evaluated for mid-course response. The investigated baseline markers of the GeparTrio study and their impact on mid-course as well as pCR is outlined in Table 1 . The overall pCR rate, defined as no invasive tumor residuals in the breast and no involved lymph nodes at surgery (ypT0/ypTis, ypN0 = RG5 ? RG3a) was 20.5%. A regression grade 5 defined as no invasive and no non-invasive residuals (ypT0, ypN0 = RG5) could be seen in 16.7% of the patients (Supplmentary Table S1b ).
Predictors of mid-course response and pCR at surgery in univariate analysis including baseline clinicopathological factors Single factors, significantly associated with the achievement of mid-course response as well as a pCR at surgery in the univariate analysis were: age below 40 years, a non-T4 tumor, high-tumor grade (G3), ER, and PgR negative. Tumor stage, nodal involvement and HER2 status neither had an impact on mid-course response nor on pCR (Table 2) . Non-lobular tumor type had a significant impact only on pCR.
Impact of several factors on pCR rates in different age groups according to histological subtypes and HER2 expression
Age at diagnosis
About 17.4% of the patients were below the age of 40 years with a pCR rate of 31.0%. Pathological complete response was significantly higher in patients under the age of 40 years compared to those 40 years or older (Fig. 2a) . The highest pCR rate could be detected for those under 40 years with an ER/PgR negative (P = 0.001) or an undifferentiated (P = 0.001) tumor. When a tumor was triple negative pCR rates almost doubled and were as high as 57% in the \40 years population compared to 34% in the patients C40 years (P \ 0.0001).
Histological tumor type
The pCR rate for lobular-invasive tumors (n = 277) was significantly lower than for the ductal-invasive tumors (9.4% vs. 22.2%; P = 0.0001). (Fig. 2b E R a n d P g R n e g a t iv e E R a n d / o r P g R HER2-positive and HER2-negative patients varied in the different subgroups (Fig. 2c) .
In the multivariable analysis age, grading and hormone receptor status were independent predictive factors for mid-course response after two cycles of TAC (Table 2) . Young age (OR 1.623; P = 0.0043), non-T4 tumors (OR 1.81; P = 0.0139); grade 3 tumors (OR 1.93; P \ 0.0001), a non-lobular histology (OR 2.29; P = 0.0052), and negative hormone receptor status (OR 3.08; P \ 0.001) predicted significantly, independently a pCR at surgery. A negative hormone receptor status was the strongest single predictive factor ( Table 2 ). The ROC curve for the multivariable logistic regression model shows an area under the curve of 0.727. (Fig. 3) .
HER2 status and ER and PgR were used to further subclassify the tumors (Methods section). The rate of midcourse response and pCR rate at surgery of the four biological subgroups is given in Supplementary Table S1a. The significant predictors for the overall cohort (age, grading, tumor stage, and histological subtype) were further tested within the biological subgroups. Patients with a luminal A tumor had only a probability to have a pCR rate above 10% with grade 3 tumors. The multivariable analysis revealed only grading as an independent factor within the luminal A and B subgroup. Within the HER2 like group the clinical tumor stage at baseline was an independent factor. Age was the only independent factor within the triple negative subgroup (Table 3 ). The histological subtype gave no independent information in any of the biological subgroups. Besides the triple negative subgroup, pCR rates were lower in the lobular than in the ductal group but results did not reach statistical significance. Within the triple negative group age (84.8% age \ 40 vs. 73.6% age C 40; P = 0.039) and grading were significant predictors to reach mid-course response after TAC 92 in the univariable analysis. Grade 3 remained an independent significant predictive factor [80.5% vs. 67.9%; P = 0.01; OR 1.93 (95% CI 1.17-3.18)]. No factor could be found to determine mid-course response within the other biological subgroups.
Early responders and non-responders
Within the non-responder group, no subgroup could be identified which benefitted from the more intense therapy with 69 TAC neither by classical factors nor by biological subtyping.
In the responder group patients with a HER2 like tumor seemed to have a higher pCR rate with TAC 98 (27.4% TAC 96 vs. 44.2% TAC 98; P = 0.026) (Supplementary Table S2 ).
Discussion
In this analysis, it could be demonstrated that biological factors combined with clinical and pathological information can be used both to predict pathological as well as mid-course response to neoadjuvant TAC chemotherapy in patients with primary breast cancer. In univariate testing, there was a high concordance of factors predicting an early clinical response after two cycles TAC and those that predict a pCR at surgery. Only histological type was exclusively predictive for pCR at surgery. In multivariate testing, all these factors provided independent information for predicting a pCR at surgery.
In contrast to some other trials, HER2 as a single marker had neither predictive value for mid-course response nor for pCR [3, 10] . None of the HER2-positive patients received trastuzumab at that time. Therefore, this trial has the capability to evaluate biomarkers predicting response to chemotherapy alone in a HER2-positive group of patients. Nevertheless, HER2 status gave different predictive information depending on the ER/PgR status of the tumor, reflecting the biological phenotypes. In patients with luminal tumors, the pCR rate in the luminal B group including also HER2 positive cases, was higher than in the luminal A group. Similar results were seen by Guarneri et al. [11] in a pooled analysis of multiple neoadjuvant trials with different chemotherapy regimens. The pCR rate in the HR? and HER2 positive tumors was significantly higher than for those with an HR? and HER2 negative Fig. 3 Receiver operating characteristic curve for the pathologic complete response to TAC-based chemotherapy using the factors which gave significantly independent information for pCR. The area under the ROC curve including age, grading, ER/PgR status, histological tumor type, and clinical T stadium is 0.727 tumor (15% vs. 6%). These results are matching those from the Geparduo trial in a smaller set of 116 patients with a pCR rate of only 1.8% for the HR?/HER2-compared to 23.1% for the HR?/HER2? group [1] . Absolute values might differ between different analyses but should not be overestimated.
Using the Sorlie classification, several breast cancer subtypes with distinct gene expression patterns and different prognoses can be identified [12] . Immunohistochemically, this classification is so far mainly based on the ER, PgR, and HER2 status. Patients with tumor features suggestive for the luminal subtype have in general a low pCR rate, and grading was of utmost importance in our investigation for selecting those patients with an expected pCR rate [10%. However, one would like to have integrated those parameters as well as molecular information into one test. Several strategies have been undertaken to select those luminal patients with a higher probability for a pCR, e.g., using the Genomic Grade Index (GGI) or the Neoadjuvant Luminal Response Score (NLRS) [13, 14] . The GGI compared to conventional parameters adds only modest but still independent predictive information. The NLRS will be able to select those luminal tumors which will have a chance for pCR above 10% to prevent overtreatment.
Our study had several strengths and limitations. Above all, one strength was the sample size which provided robust evidence and allowed to draw conclusions for the smaller subgroups of patients. This analysis has prospectively been planned for all markers included. Most identified factors were predictive not only for a pCR at surgery but also for a mid-course response. The study was a good model for evaluating biomarkers also in HER2 positive patients because a combination chemotherapy alone without trastuzumab was used.
In this analysis, for predictive factors, we used here the more recent and now generally accepted pCR definition that requires a tumor-free axilla, but allowed remaining DCIS (ypT0/ypTis ypN0), taking into account that noninvasive residuals do not negatively influence the longterm outcome [15] . In the separate analysis of the responding and non-responding patients, the definition of pCR was the absence of all invasive and non-invasive tumor cells in the removed breast tissue irrespective of the axillary involvement. Even though the numbers were slightly different when using these different definitions, the predictive power of the examined factors did not change (data not shown).
One limitation might be that mid-course responders and non responders did not receive the same therapy. We considered this procedure as acceptable since in those patients who did not respond after two cycles of TAC, the response to NX was not significantly inferior to four additional cycles of TAC. Information regarding the biological factors could not be obtained from all patients. However, except for the HER2 status, which was missing in 17% of the patients at primary diagnosis (still available for a total of 1,717 patients), all other factors were known for more than 90% of the study population. Our study shows, that even in the time of gene array analyses, pCR can be reliably predicted by clinical and standard histopathological parameters in addition to the biological phenotype [16] . In addition, we could identify clinico-biological marker combinations which significantly predicted a mid-course response after two cycles of TAC as well as a pCR at surgery. Grading was of great importance to select the patients within the luminal subtype of the tumors who would have a higher pCR rate. Age added valuable information in the chemosensitive groups, e.g., those with a triple negative phenotype which underlines the fact that the triple negative is a mixed population of different tumor types, where those without pCR have an extremely poor prognosis [17, 18] . A different biological behavior between invasive lobular and invasive ductal breast carcinomas has been described for the adjuvant and neoadjuvant setting [19] [20] [21] . In our study, a total of 277 patients with lobular histology were evaluated and confirmed that this subtype is less sensitive to chemotherapy and will only benefit if other biomarkers defining aggressive behavior as grade 3 or ER/PgR negativity were apparent.
This analysis might help to guide the clinician in the decision making process for neoadjuvant therapy. Those patient populations with a pCR rate of less than 10% might not be the adequate candidates for NACT with the regimen used in this study. Our results may help to further sharpen the profile of the eligible patient population for future trials evaluating new tools like gene expression signature arrays in order to identify predictive marker sets for NACT in the specific subgroups [22] .
